Zenarestat

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1991-2016
01219912016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
The dorsal root ganglia (DRG) have been identified as the target tissue in diabetic somatosensory neuropathy. It has been… (More)
Is this relevant?
2004
2004
OBJECTIVE The aim of this study was to report the baseline and natural progression of diabetic peripheral neuropathy over 12… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2002
2002
The crystal structure of the complex of human recombinant aldose reductase (AR) with zenarestat, one of its potent inhibitors… (More)
Is this relevant?
2001
2001
The effects of zenarestat, an aldose reductase inhibitor, on endoneurial blood flow (NBF) were explored in streptozotocin-induced… (More)
Is this relevant?
2000
2000
We studied the effects of zenarestat, an aldose reductase inhibitor (ARI), on peripheral neuropathy in Zucker diabetic fatty (ZDF… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
OBJECTIVE To determine whether the aldose reductase inhibitor (ARI) zenarestat improves nerve conduction velocity (NCV) and nerve… (More)
Is this relevant?
1994
1994
Zenarestat, (3-(4-bromo-2-fluorobenzyl)-7-chloro-2,4-dioxo-1,2,3,4- tetrahydroquinazolin-1-yl) acetic acid, an aldose reductase… (More)
Is this relevant?
1992
1992
1. Mice show a sex difference in the excretion of zenarestat similar to that seen in rats, but dogs and humans show no… (More)
Is this relevant?
1991
1991
1. Rat shows a marked sex difference in the excretion of 14C-zenarestat: only 1% of the dose was excreted in the urine of males… (More)
Is this relevant?
1991
1991
1. Age-dependent changes in urinary excretion of zenarestat and the effect of gonadectomy and androgen treatment were… (More)
Is this relevant?